January 2019 in “Jui rinsho hifuka” A dog's skin and digestive problems improved after treatment for thyroid cancer.
13 citations
,
July 2024 in “Heart Failure Reviews” The apelinergic system might protect the heart from damage caused by doxorubicin.
A 72-year-old man was diagnosed with a rare skin form of Rosai-Dorfman disease after years of misdiagnosis.
2 citations
,
May 2023 in “The Journal of Immunology” NXC736 significantly reduced hair loss in mice with alopecia areata.
October 2014 in “Cancer research” Blocking mTORC1 reduces skin tumor growth in mice.
September 2025 in “BULLETIN OF STOMATOLOGY AND MAXILLOFACIAL SURGERY” Better supportive care is needed to manage chemotherapy side effects.
11 citations
,
January 2021 in “Breast Care” Patients prioritize quality of life, overall survival, and progression-free survival in treatment decisions for advanced breast cancer.
March 2026 in “Preprints.org” Plerixafor may help treat pigmentation disorders by promoting skin repigmentation.
October 2019 in “Research Square (Research Square)” YH0618 granules may help prevent hair loss in breast cancer patients undergoing chemotherapy.
25 citations
,
June 2024 in “Pharmaceutics” Scaffold-based drug delivery systems improve oral cancer treatment by targeting drugs directly to cancer cells, reducing side effects.
April 2024 in “Journal of pharmacy & pharmacognosy research” A compound from Calophyllum inophyllum L. leaf may help treat non-small cell lung cancer.
Treatments for acute leukaemia lead to high remission rates, but relapses occur, requiring ongoing advancements in care.
6 citations
,
December 2021 in “Journal of Cancer Research and Therapeutics” The treatment improved survival and controlled cancer spread but required managing side effects like rashes.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
1 citations
,
June 2024 in “Journal of Clinical Oncology” Aumolertinib is effective and well-tolerated for treating advanced lung cancer with EGFR mutations.
Nanoformulations improve luteolin's effectiveness as a cancer treatment.
January 2026 in “Frontiers in Pharmacology” Wedelolactone may help treat inflammation, infections, cancer, bone loss, and organ damage.
278 citations
,
May 2013 in “Ca” Targeted anticancer therapies can cause severe side effects similar to traditional chemotherapy, but with different types.
84 citations
,
August 2023 in “Drugs” Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.
11 citations
,
October 2020 in “PLoS ONE” Cooling can protect hair follicles from chemotherapy damage by reducing drug uptake.
48 citations
,
October 2004 in “Molecular and Cellular Biology” Mice with a specific BRCA1 mutation have a higher risk of tumors, especially in the uterus and ovaries.
June 2026 in “Dermatology and Therapy” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
November 2013 in “Cancer” Oophorectomy reduces ovarian cancer risk for women with BRCA mutations, finasteride lowers prostate cancer risk without raising death risk, and prophylactic mastectomy rates are rising.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.
137 citations
,
December 2006 in “Arthritis Research & Therapy” Mycophenolate mofetil is safer and more effective than cyclophosphamide for treating lupus nephritis.
4 citations
,
October 2013 in “PLoS ONE” Vemurafenib causes significant skin side effects, requiring regular dermatologist care and sun protection.
11 citations
,
January 1999 in “Dermatology” 4 citations
,
March 2023 in “IP International Journal of Comprehensive and Advanced Pharmacology” The new drug delivery system improves exemestane's absorption and effectiveness.
October 2024 in “Journal of Dental Sciences” Effective treatments for discoid lupus erythematosus are needed, as current options are unsatisfactory and off-label.
January 2025 in “AYUSHDHARA” Herbomineral drugs effectively manage chemotherapy-induced diarrhea in oral cavity cancer patients.